Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

NCT05551741 is registered in ClinicalTrials.gov with Immunobrain Checkpoint as lead sponsor.

NCT NCT05551741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05551741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)
Lead sponsor
Immunobrain Checkpoint
Phase
Phase 1
Overall status
Completed
Start date
March 2, 2023
Completion date
December 16, 2025
Enrollment
40 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease